Ductal Carcinoma in Situ offers clues on Therapy for Cancer

Ductal Carcinoma in Situ offers clues on Therapy for CancerIn a report tracked nearly 1,200 women who received diagnoses of ductal carcinoma in situ, or D. C. I. S, which is often referred to as precancer because the risky cells have not moved outside the milk duct. In the study, about 28 percent of the women fell into high risk category and also determined that when D. CI. S is detected by breast exam rather than by mammography. The findings are believed to be an important step toward more personalized cancer treatment; however that were not likely to change practice any time soon.

Dr. Susan Love, the clinical professor of surgery at the David Geffen School of Medicine at the University California, Los Angeles, said, ""It's a great study and a good example of how we can decrease over treatment by identifying markers which can tell us which lesions are the good ones versus which are likely to become invasive and deserve more aggressive treatment". Study researcher Karla Kerlikowske , MD, of University of California , San Francisco , tells Kerlikowske said, ""But the study gets us closer to our goal of separating women with DCIS into risk groups, so as to avoid over treatment of women with low-risk breast lesions and under treatment of women with high-risk lesions,"

A total of 17.3 percent the researchers stratified were in the lowest risk group and 1,162 women into four risk groups with only a 4.1 percent chance of developing invasive cancer at eight years. With nearly 20 percent chance of developing invasive cancer at eight years, a total of 27.6 percent of the women were in the high risk group.